The American College of Obstetricians and Gynecologists (ACOG), the Society for Women’s Health Research (SWHR), and the Women First Research Coalition (WFRC) officially introduced a landmark policy framework on July 15, designed to address decades of systemic inequities in the American medical landscape. Known as the National Strategy to Close the Women’s Health Gap, the proposal issues a direct call to the United States Congress to authorize a sustained investment of $20 billion over the next decade. This funding is intended to overhaul the infrastructure of women’s health research, modernize clinical care pathways, and improve health outcomes for more than 160 million women across the nation.
The initiative arrives at a critical juncture in American healthcare, as providers and advocates increasingly highlight the disparities in funding and attention given to female-specific conditions. The strategy has quickly garnered broad institutional support, with the Endocrine Society joining a coalition of more than 20—and eventually more than 35—professional medical societies, patient advocacy groups, and research organizations to endorse the framework. The collective goal is to move beyond the incremental changes of the past thirty years and establish a coordinated, well-funded national mandate that recognizes women’s health as a cornerstone of public health and economic stability.
Historical Context and the Evolution of Women’s Health Policy
To understand the necessity of the National Strategy, it is essential to review the legislative history of medical research in the United States. For much of the 20th century, clinical trials and medical research predominantly focused on male subjects. Women were often excluded from early-stage research due to concerns regarding hormonal fluctuations and potential reproductive risks, leading to a "male as default" paradigm in medicine.
A major shift occurred in 1993 with the passage of the NIH Revitalization Act. This landmark legislation required the National Institutes of Health (NIH) to ensure that women and members of minority groups were included in all NIH-funded clinical research. While this law succeeded in increasing female participation in trials, critics and medical professionals argue that it did not go far enough. Inclusion in a study does not necessarily mean that the data is analyzed for sex-based differences, nor does it guarantee that conditions primarily affecting women receive a proportionate share of federal research dollars.
Over the three decades since the 1993 Act, significant gaps have persisted. Research indicates that women are still diagnosed later than men for various conditions, including heart disease and certain cancers, and they experience higher rates of adverse drug reactions because many pharmaceuticals were originally calibrated for male physiology. The National Strategy to Close the Women’s Health Gap seeks to address these "implementation gaps" by ensuring that scientific discovery is not just inclusive in theory, but transformative in practice.
The $20 Billion Framework: Five Key Priorities
The strategy outlines a comprehensive roadmap for Congress, emphasizing that a one-time infusion of capital is insufficient. Instead, it calls for a sustained $2 billion annual commitment over ten years, distributed across five strategic pillars:
1. Scaling Research Funding
The primary objective is to increase the volume and quality of research focused on conditions that solely or disproportionately affect women. This includes reproductive health issues like endometriosis and uterine fibroids, as well as chronic conditions like autoimmune diseases, where women represent approximately 80% of all cases. By bridging the "valley of death"—the gap between laboratory discovery and clinical application—the strategy aims to accelerate the development of new diagnostics and therapies.
2. Strengthening the Research and Clinical Workforce
A core component of the strategy is the investment in human capital. ACOG Chief Executive Officer Sandra E. Brooks, MD, MBA, FACOG, emphasized that closing the gap requires a robust pipeline of specialists. This includes providing grants and incentives for researchers who specialize in sex-based biology and ensuring that the clinical workforce is trained to recognize and treat the unique manifestations of disease in women.
3. Modernizing Data and Metrics
The strategy calls for the standardization of sex-disaggregated data. Currently, medical data is often siloed or fails to account for sex as a primary biological variable. By modernizing how data is collected and reported across federal agencies, the strategy intends to provide a clearer picture of how diseases progress in women, thereby enabling more personalized and effective treatment plans.
4. Updating Policy and Regulatory Standards
Advocates are pushing for regulatory updates at the FDA and NIH to ensure that sex-based differences are a mandatory consideration in the approval of new medical devices and pharmaceuticals. This includes updating clinical trial protocols to reflect the lifespan of a woman, from puberty through menopause and into healthy aging.
5. Enhancing Access to Evidence-Based Clinical Care
The final priority focuses on the delivery of care. Scientific breakthroughs are of little use if they do not reach the patient. The strategy advocates for policies that improve the translation of research into clinical practice, ensuring that every woman, regardless of geography or socioeconomic status, has access to the highest standard of evidence-based care.
Supporting Data: The Economic and Health Imperative
The push for a $20 billion investment is supported by a growing body of economic and medical data. According to a report by the McKinsey Global Institute, closing the women’s health gap could add $1 trillion to the global economy annually by 2040. This economic boost would result from increased labor force participation, fewer sick days, and the extended productivity of women who are able to manage chronic conditions more effectively.
In the United States, the statistics regarding women’s health outcomes highlight the urgency of the coalition’s demands. The U.S. continues to face a maternal mortality crisis that is significantly worse than that of other high-income nations, with particularly stark disparities affecting Black and Indigenous women. Furthermore, conditions like endometriosis, which affects one in ten women, often take an average of seven to ten years to diagnose, leading to years of unnecessary pain and lost productivity.
The Endocrine Society’s involvement underscores the biological complexity of the issue. President Nanette Santoro, MD, noted that hormones influence nearly every aspect of health, from metabolism and bone density to cardiovascular function and mental health. "Because hormones influence nearly every aspect of women’s health, advancing research in this area has the potential to improve millions of lives," Dr. Santoro stated. The Society argues that by focusing on endocrine research, the medical community can unlock better treatments for polycystic ovary syndrome (PCOS), menopause-related symptoms, and thyroid disorders, all of which have a profound impact on a woman’s quality of life.
Broad Coalition and Institutional Support
The strength of the National Strategy lies in its diverse and extensive list of endorsers. The coalition represents a "who’s who" of the American medical establishment, signaling that the move to close the health gap is no longer a niche advocacy issue but a mainstream medical priority.
Endorsing organizations include:
- Specialty Societies: American Heart Association, American Society for Reproductive Medicine, Society for Maternal-Fetal Medicine, and the American Urogynecologic Society.
- Disease-Specific Advocates: The Arthritis Foundation, Lupus Foundation of America, National MS Society, and the Alzheimer’s Association (via the Women’s Alzheimer’s Movement).
- Life-Stage Organizations: March of Dimes, Let’s Talk Menopause, and the Alliance for Aging Research.
- Equity-Focused Groups: Black Women’s Health Imperative and the White Dress Project (focused on uterine fibroids).
Kathryn Schubert, MPP, CAE, President and CEO of SWHR, highlighted that the gap has persisted "for far too long" and that the strategy provides Congress with a clear "roadmap to improve health outcomes, drive innovation, and build a healthier future for women, families, and communities."
Analysis of Implications and Future Outlook
The introduction of the National Strategy to Close the Women’s Health Gap represents a shift toward a "whole-of-government" approach. While the $20 billion request is ambitious, it aligns with recent executive actions. In early 2024, the White House launched the Initiative on Women’s Health Research, led by First Lady Jill Biden, which also called for increased federal investment and better coordination across agencies.
The implications of this strategy, if adopted by Congress, would be felt across the entire healthcare ecosystem. For the pharmaceutical industry, it would mean more rigorous standards for sex-based clinical data. For the academic community, it would mean a surge in available grant funding for sex-based biological studies. For the average patient, it could mean shorter times to diagnosis, more effective treatments with fewer side effects, and a healthcare system that views her health as a lifelong continuum rather than a series of isolated reproductive events.
However, the path to securing $20 billion in federal funding remains challenging given the current fiscal environment and legislative gridlock. Supporters of the strategy argue that the cost of inaction—measured in lost productivity, high emergency room utilization, and preventable maternal deaths—far outweighs the $2 billion annual price tag.
As the proposal moves to Capitol Hill, the coalition of over 35 organizations plans to engage in intensive advocacy efforts. Their message is clear: the 1993 Revitalization Act was a beginning, not an end. To truly achieve health equity, the United States must commit to a dedicated, long-term investment that recognizes the biological and social realities of women’s health. By strengthening research, modernizing policy, and investing in the workforce, the National Strategy aims to ensure that scientific discovery finally serves the needs of the majority of the population.
